ArticleAsian Pacific journal of cancer prevention : APJCP2026
The Dual Role of ABCG2 Copy Number Variation: A Protective Factor in Cancer Risk, and a Prognostic Marker for Survival in Thai Breast Cancer.
Article in Asian Pacific journal of cancer prevention : APJCP, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to investigate CNVs of MDR1 and ABCG2 and their associations with clinicopathological characteristics and survival outcomes in Thai breast cancer patients.
methodsGenomic DNA from 126 breast cancer patients and 162 healthy controls was analyzed. CNVs were determined using real-time PCR and the ∆Ct method. Associations with clinicopathological parameters were assessed using the Chi-square test. Kaplan-Meier survival analysis and the log-rank test, were used to evaluate overall survival.
resultThe ABCG2 >1/1 genotype was significantly more common in controls than in patients (OR = 0.32, 95% CI: 0.19-0.525, P < 0.001), suggesting a protective role. MDR1 CNVs showed no significant difference between groups. Among breast cancer patients, the MDR1 >1/1 genotype was associated with larger tumor size (>3 cm) and distant metastasis (P = 0.037, 0.008), while the ABCG2 >1/1 genotype was correlated with progesterone receptor positivity and distant metastasis (P = 0.005, 0.046). Survival analysis revealed that ABCG2 >1/1 was associated with shorter overall survival (P = 0.013), whereas MDR1 CNVs showed no significant association with survival (P = 0.127).
conclusionThese findings suggest that copy number variations (CNVs) in ABCG2 may serve as both protective and prognostic markers in breast cancer, while MDR1 CNVs may be associated with tumor aggressiveness. Both genes hold potential as biomarkers for breast cancer pathogenesis, clinicopathological characteristics, and survival outcomes in Thai breast cancer patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.